Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sandra M Arend

Showing results (31-40 of 47) with videos related to

Pageof 5
Sort By:
The Journal of Clinical Investigation|February 21, 2018
Mycobacterial growth inhibition is associated with trained innate immunitySimone A Joosten, Krista E van Meijgaarden, Sandra M Arend, et al.
Infection and Immunity|April 16, 2002
Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosisAnnemieke Geluk, Krista E van Meijgaarden, Kees L M C Franken, et al.
The European Respiratory Journal|April 13, 2012
Role of the QuantiFERON(R)-TB Gold In-Tube assay in screening new immigrants for tuberculosis infectionChristiaan Mulder, Henk van Deutekom, Erik M Huisman, et al.
Tuberculosis (Edinburgh, Scotland)|July 22, 2018
Borderline QuantiFERON results and the distinction between specific responses and test variabilityJonathan W Uzorka, Ailko W J Bossink, Willeke P J Franken, et al.
Vaccine|March 16, 2010
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteersJaap T van Dissel, Sandra M Arend, Corine Prins, et al.
Clinical Pharmacokinetics|October 11, 2021
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic StudyDirk Jan A R Moes, David J van Westerloo, Sandra M Arend, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 21, 2018
A novel view on the pathogenesis of complications after intravesical BCG for bladder cancerManu P Bilsen, Krista E van Meijgaarden, Hanna K de Jong, et al.
Infection and Immunity|September 10, 2009
Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteriaMay Young Lin, T B K Reddy, Sandra M Arend, et al.
American Journal of Respiratory and Critical Care Medicine|December 16, 2006
Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contactsSandra M Arend, Steven F T Thijsen, Eliane M S Leyten, et al.
The European Respiratory Journal|January 21, 2022
Biomarkers to identify <i>Mycobacterium tuberculosis</i> infection among borderline QuantiFERON resultsJonathan W Uzorka, Jaap A Bakker, Krista E van Meijgaarden, et al.
Pageof 5

Showing results (31-40 of 47) with videos related to

Sort By:
Pageof 5
The Journal of Clinical Investigation|February 21, 2018
Mycobacterial growth inhibition is associated with trained innate immunitySimone A Joosten, Krista E van Meijgaarden, Sandra M Arend, et al.
Infection and Immunity|April 16, 2002
Identification and characterization of the ESAT-6 homologue of Mycobacterium leprae and T-cell cross-reactivity with Mycobacterium tuberculosisAnnemieke Geluk, Krista E van Meijgaarden, Kees L M C Franken, et al.
The European Respiratory Journal|April 13, 2012
Role of the QuantiFERON(R)-TB Gold In-Tube assay in screening new immigrants for tuberculosis infectionChristiaan Mulder, Henk van Deutekom, Erik M Huisman, et al.
Tuberculosis (Edinburgh, Scotland)|July 22, 2018
Borderline QuantiFERON results and the distinction between specific responses and test variabilityJonathan W Uzorka, Ailko W J Bossink, Willeke P J Franken, et al.
Vaccine|March 16, 2010
Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteersJaap T van Dissel, Sandra M Arend, Corine Prins, et al.
Clinical Pharmacokinetics|October 11, 2021
Towards Fixed Dosing of Tocilizumab in ICU-Admitted COVID-19 Patients: Results of an Observational Population Pharmacokinetic and Descriptive Pharmacodynamic StudyDirk Jan A R Moes, David J van Westerloo, Sandra M Arend, et al.
International Journal of Infectious Diseases : IJID : Official Publication of the International Society for Infectious Diseases|May 21, 2018
A novel view on the pathogenesis of complications after intravesical BCG for bladder cancerManu P Bilsen, Krista E van Meijgaarden, Hanna K de Jong, et al.
Infection and Immunity|September 10, 2009
Cross-reactive immunity to Mycobacterium tuberculosis DosR regulon-encoded antigens in individuals infected with environmental, nontuberculous mycobacteriaMay Young Lin, T B K Reddy, Sandra M Arend, et al.
American Journal of Respiratory and Critical Care Medicine|December 16, 2006
Comparison of two interferon-gamma assays and tuberculin skin test for tracing tuberculosis contactsSandra M Arend, Steven F T Thijsen, Eliane M S Leyten, et al.
The European Respiratory Journal|January 21, 2022
Biomarkers to identify <i>Mycobacterium tuberculosis</i> infection among borderline QuantiFERON resultsJonathan W Uzorka, Jaap A Bakker, Krista E van Meijgaarden, et al.
Pageof 5